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Background: Smoking crack involves the risk of transmitting diseases such as HIV and hepatitis C (HCV). The
current study determines whether the formerly unsanctioned supervised smoking facility (SSF)—operated by the
grassroot organization, Vancouver Area Network of Drug Users (VANDU) for the last few years—costs less than the
costs incurred for health-care services as a direct consequence of not having such a program in Vancouver, Canada.
Methods: The data pertaining to the attendance at the SSF was gathered in 2012–2013 by VANDU. By relying on
this data, a mathematical model was employed to estimate the number of HCV infections prevented by the former
facility in Vancouver’s Downtown Eastside (DTES).
Results: The DTES SSF’s benefit-cost ratio was conservatively estimated at 12.1:1 due to its low operating cost. The
study used 70% and 90% initial pipe-sharing rates for sensitivity analysis. At 80% sharing rate, the marginal HCV
cases prevented were determined to be 55 cases. Moreover, at 80% sharing rate, the marginal cost-effectiveness
ratio ranges from $1,705 to $97,203. The results from both the baseline and sensitivity analysis demonstrated that the
establishment of the SSF by VANDU on average had annually saved CAD$1.8 million dollars in taxpayer’s money.
Conclusions: Funding SSFs in Vancouver is an efficient and effective use of financial resources in the public health
domain; therefore, Vancouver Coastal Health should actively participate in their establishment in order to reduce HCV
and other blood-borne infections such as HIV within the non-injecting drug users.
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Smoking crack cocaine is not only on the rise in the
Canadian municipalities, but it is also often neglected by
health officials—especially so when compared to similar
inner-city health problems such as injection drug use
[1-4]. In British Columbia, the daily usage of crack cocaine
within the general population is higher than that in any
other provinces within Canada [5]. This is a pressing prob-
lem in Vancouver, where daily crack use, within a cohort
of injection drug users, increased from 7.4% in 1996 to
42.6% in 2005 [6]. Among drug users in Vancouver’s
Downtown Eastside (DTES), the rate of crack use has
been reported to be as high as 86.6% [7]. The use of crackCorrespondence: eja2@sfu.ca
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unless otherwise stated.is associated with several other risks when compared to
the tendencies displayed by other drug-using populations.
For example, crack users are more likely to have unstable
housing [8], be involved in sex work [9], participate in
risky behavior [10-12], engage in criminal activity [13,14],
experience multiple health problems [5], and are less likely
to access social and health services [15].
Research conducted upon a cohort of crack-user
population in Vancouver’s DTES revealed that partici-
pants had reported 80% sharing rate as it is related to
their drug smoking paraphernalia [16,17]. Studies have
shown a higher-than-average prevalence of human im-
munodeficiency virus (HIV), hepatitis C virus (HCV),
and tuberculosis in users of crack cocaine who report no
injection drug use [17]. However, the evidence of the rela-
tionship between non-injecting drug use and HIV/HCV
infection is ambiguous. Some researchers have suggestedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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volved in unsafe sexual behavior [18] and that HCV
transmission in NIDUs is associated with tattooing [19].
Some researchers have stirred up a controversy in sug-
gesting that NIDUs are essentially injecting drug users
(IDUs) who have failed to report their route of trans-
mission accurately [20].
Nevertheless, research conducted on NIDUs suggests
that infectious diseases may have been transmitted by
the sharing of crack pipes [21,22]. In fact, most users are
oblivious to the risks involved in sharing drug tools [21].
Some researchers postulate that HIV and HCV transmis-
sion can be accounted for by the high prevalence of oral
lesions in crack smokers. Some of these include sores,
blisters, and cuts on their lips and oral cavities—caused
because of the mouth and lips coming in contact with
hot glass, hot smoke, and the sharp edges of glass pipe
stems or metal pipe stems [21]. The lack of knowledge
with respect to transmittable diseases further engenders
and reinforces the reckless exchange of drug equipment.
In fact, a study demonstrated that 2% of crack pipes
tested positive for HCV [23].
Scientific evaluation of Insite, North America’s first
and only supervised injection facility, showed that it has
successfully reduced needle sharing and overdose death
while concurrently improving service uptake and public
order within the DTES [24-26]. Despite the improve-
ment of conditions in the DTES after the opening of
Insite, Vancouver is still riddled with concerns regarding
public health and order related to drug use, including
crack and crystal methamphetamine [27,28]. Accordingly,
the region’s health authority has shown some interest in
applying for an exemption under the Controlled and Sub-
stance Act of the Criminal Code of Canada to open a su-
pervised smoking facility (SSF) in the DTES. However, the
concept of a government-sanctioned SSF is somewhat
controversial, particularly because the potential impact
and benefits of such a facility are unknown.
Therefore, the present research was conducted to deter-
mine whether a case could be made for the establishment
of SSFs in the DTES of Vancouver. Specifically, the current
study analyzed the cost-benefits and cost-effectiveness of
the only SSF in Canada, operated by Vancouver Area
Network of Drug Users (VANDU) without a license for
a few years. The SSF mentioned above was located in
VANDU’s front office in the DTES, along East Hastings
Street. VANDU has over 800 volunteers, 1,300 active
members [29], and a Board of Directors composed of
current and former users. See Figure 1 for the location
of VANDU in the DTES.
In December of 2013, VANDU was forced to shut
down the SSF under the direction of their funding
agency, the Vancouver Coastal Health. Using mathemat-
ical modelling with conservative parameter estimates,this analysis estimated the number of HCV infections
prevented as a result of SSF. The savings from illnesses
avoided were compared to the operational cost of a SSF.
The analysis was eventually extended to consider the
impact of opening additional SSFs in the DTES.
Methods
Background
VANDU operates on an annual budget of CAD$200,000
funded through Vancouver Coastal Health. One of their
various programs included the operation of an unsanc-
tioned SSF. The smoking room was operated by peers
and was accessible to one person at a time. There would
be an unusually big lineup to use the room that con-
tained a fan. Within VANDU, NIDUs would generally be
provided with a ‘safer crack use kit’ that contained the
following: mouth pieces, wooden push sticks, screens, al-
cohol swaps, and heat-resistant and shatter-proof glass
pipes which minimized chances of injury to the users’
lips and mouth. See Figure 2 for materials contained in
the ‘safer crack use kit’ provided at VANDU.
Moreover, VANDU’s SSF provided a clean and safe en-
vironment within which one could use pre-obtained illicit
drugs, get medical attention in the event of an over-
dose, and obtain access or referral to primary health
care when required. This study was approved by Simon
Fraser University Research Ethics Board (study number:
2013 s0058). VANDU’s Executive Board also approved the
study since it corresponded with its philosophy and the
demand that all projects directly involve its members.
Model
For this analysis, it was necessary to calculate the effects
of both providing clean equipment as well as that of
adopting safer smoking behaviors. Along the lines of re-
search conducted on the economic impact of a needle
exchange program in Edmonton, Alberta, Canada, this
study uses a mathematical model to estimate the num-
ber of HCV infections that could be prevented through
the establishment of a SSF [30]. The number of new
HIV infections avoided, A, is calculated as follows:
A ¼ INsd 1− 1−qtð Þm½ ;
where m is the number of sharing partners when pipes
are shared, t is the probability of HCV transmission when
using an HCV-infected pipe, s is the rate of pipe sharing, I
is the proportion of NIDU population that is HCV nega-
tive, N is the number of pipes in circulation, d is the per-
centage of pipes not cleaned before use, and q is the
proportion of the NIDU population that is HCV positive.
Initially, this study was meant to use a few other math-
ematical models such as those of Kaplan and O’Keefe [31],
Lurie and Drucker [32], Gold et al. [33], Laufer [34], and
Figure 1 Map of the DTES.
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the rate of HIV transmission from a single pipe and the
rate of secondary transmission, this analysis had to rely on
the Jacobs et al. [30] model. However, the model employed
in the current study has previously been adopted by four
different studies [37-40], which have found that this
model is the best choice for predicting actual and po-
tential cases of HIV and HCV in a Canadian setting.
Moreover, the model employed in this study has suc-
cessfully produced estimates of HIV and HCV cases
within the IDU population—similar to known data
widely cited in peer-reviewed reports.
Additionally, this study also uses behavior change in-
corporated by previous costing studies conducted onsupervised injection facilities [37-41] because of the em-
pirical evidence it provides [24,35,41,42]. Although pre-
vious costing studies often go wrong when it comes to
using caution and employing an odd ratio of 0.60, this
study uses the point estimate of 0.30 used by previous
studies [37-42] and estimated by Kerr et al. [24]. The
data collected by VANDU during 2012–2013 pertains to
the number of visits per month to the SSF.
Variables and parameters
Medical and scientific literatures were used in cases when
Vancouver-specific data was not available. Where estimates
differed, this study used the lower bound, so all estimates
remain conservative. The concept of behavioral change in
Figure 2 Content materials of a ‘safer crack use kit’ provided
at VANDU.
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ioral changes related to IDU needle-sharing behavior out-
side of the SIF in Vancouver. Kerr et al. [24] and Bravo
et al. [43] found that IDUs who relied upon SIFs were also
able to reduce their needle-sharing activities outside of the
facility up to a significant extent. Table 1 provides the esti-
mates and variables used in the model (please note that
percentages need to be converted to fractions when im-
puting the variables in the model).
Consequently, it was presumed that NIDUs that vis-
ited the unsanctioned SSF were less likely to share their
pipes with others outside of the facility. Furthermore, if
a second SFF was established, the behavioral change on
pipe sharing would occur only if new NIDUs became users
of SSF [28]. On the contrary, if the SSF was frequented by
the current users, thereby restricting its use to current
users simply indulging in some additional smoking, no fur-
ther behavioral changes can be assumed. Accordingly, be-
havioral change is only accounted for in the second facility.Table 1 Sources for variables used in mathematical
modelling
Variable Value Source
Rate of pipe sharing (s) 80.0% Ivsins et al. [44]
Number of pipes in
circulation (N)
90,000 VANDU [45], Mui [46]
Percentage of pipes
not cleaned (d)
33.0% Scheinmann et al. [47]
Number of sharing partners (m) 6.30 Gyarmathy and Neaigus [48]
Proportion of crack users who
are HCV negative (I)
83.0% Fischer et al. [49]
Proportion of crack users who
are HCV positive (q)
17.0% Fischer et al. [49]
Probability of HCV infection
from single crack pipe (t)
2.00% Fischer et al. [23],
Gilbert et al. [50]Furthermore, since there was no estimated number of
crack users in the DTES of Vancouver, this number was
calculated based on the percentage of drug users (con-
servatively estimated to be around 5,000 in the DTES
[51-53]) who have smoked crack. The total number of
drug users was reported by DeBeck et al. [7] to be 86.6%
(5,000 drug users × 0.866 use crack = 4,330 crack users
in the DTES). This number was subsequently multiplied
by the number of subjects who smoked crack per day—
estimated to be around ten per day [54,55] (4,330 × 10 ×
365 days =15,804,500 smoking per year).
The number of those indulging in smoking per year
was multiplied by the percentage of pipe sharing in the
Downtown Eastside (15,804,500 smoking per year × 0.80
sharing = 12,643,600 shared crack smoking events). The
total visits to the SSF during 2012–2013 year were deter-
mined to be 23,120 per year with the average visit of
1,843 per month. Consequently, 17,696 smoking incidents
were not shared as a result of having an unsanctioned SSF
operating in the DTES (23,120 × 0.8 sharing =17,696
smoking events that were not shared). This number was
added to the behavioral change odd ratio and later
deducted from the total shared crack pipe events in
the DTES.
The medical cost of new HCV cases
HCV infection among people who use drugs is a serious
pressing concern in Canada and the United States
[56,57]. HCV infections could lead to multiple health
problems such as cirrhosis, liver failure, hepatocellular
carcinoma, and even death [58]. Accordingly, 50% of pa-
tients achieve sustained virological success to treatment
[59]. Pegylated interferon, in combination with ribavirin,
is the standard course of treatment for HCV-infected pa-
tients [57]. The range of treatment for HCV patients is
determined based on the genotype: ‘a 48-week course is
recommended for genotypes 1 and 4, whereas a 24-week
course is recommended for genotypes 2 and 3’ [57], p.
1016. Accordingly, the cost of treatment varies according
to genotype and seriousness of infections.
On an average, savings from HCV range from $20,000
per completed course of treatment per patient [60],
to $30,000 [61], and to more than $69,188 [58]. This
study uses a conservative figure of CAD$35,143 (2012
US Dollars = 33,856), as reported in [62] and utilized in
costing studies of a potential SIF in Montreal [39] and
Ottawa [40]. The conservative figure used in this study
essentially disregards the cost of the complications aris-
ing from HCV in hepatocellular carcinoma, liver failure,
and liver transplant cases.
Cost of SSF
In order to estimate the cost of operating a potential
SSF, it was important to calculate the operating cost of
Table 2 The cumulative cost-effectiveness and cost-benefit of SSF in Vancouver using Jacobs et al.’s [30] model
Variables Annual cost of operation ($) Sharing rate (%) # of HCV averted Cost-effectiveness ratio HCV ($) Cost-benefit ratio HCV
Post SSF 97,203 69 57 1,705 20.6
(78, 60) (65, 50) (1,495, 1,944) (23.5, 18.1)
Two SSF 194,406 59 109 1,784 19.7
(67, 52) (121, 93) (1,607, 2,090) (21.9, 16.8)
Three SSF 291,609 58 110 2,651 13.3
(67, 52) (121, 94) (2,410, 3,102) (14.6, 11.3)
Four SSF 388,812 58 111 3,503 10
(67, 52) (122, 94) (3,187, 4,136) (11, 8.5)
Five SSF 486,015 58 112 4,339 8.1
(67, 52) (123, 95) (3,951, 5,116) (8.9, 6.9)
Six SSF 583,218 57 113 5,161 6.8
(66, 52) (124, 95) (4,703, 6,139) (7.5, 5.7)
Seven SSF 680,421 57 114 5,969 5.9
(66, 52) (124, 96) (5,487, 7,088) (6.4, 5)
The numbers in parentheses represent the results of the sensitivity analysis (90% sharing rate, 70% sharing rate).
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ated from Monday to Friday from 10–7 pm. On week-
ends, the facility would operate from 4–7 pm. The staff
supervising the unsanctioned SSF were mostly volunteers
that were provided with a small stipend, collectively
amounting to CAD$47,203 per year. The total cost of the
rent and the safe crack kit is estimated to be CAD$50,000.
Altogether, the operating cost of the facility is estimated to
be CAD$97,203.
Results
The model used here [26] predicted the number of new
HCV cases prevented based on the pipe-sharing rate. This
included the impact of behavioral changes in pipe sharingTable 3 The marginal cost-effectiveness and cost-benefit of S
Variables Annual cost of operation ($) Sharing rate (%) # of HCV
Post SSF 97,203 69 57
(78, 60) (65, 50)
Two SSF 97,203 59 52
(67, 52) (56, 43)
Three SSF 97,203 58 1
(67, 52) (1, 1)
Four SSF 97,203 58 1
(67, 52) (1, 0.5)
Five SSF 97,203 58 1
(67, 52) (1, 0.5)
Six SSF 97,203 57 1
(66, 52) (1, 0.5)
Seven SSF 97,203 57 1
(66, 52) (1, 0.5)
The numbers in parentheses represent the results of the sensitivity analysis (90% shoutside of the SSF. The behavioral change, according to
Tables 2 and 3, was only considered twice—once for the
first SSF and once for the second SSF—based on a conser-
vative odd ratio that falls within the limit specified by [31].
As expected, the results presented in Tables 2 and 3
show that expanding SSFs would decrease HCV cases.
The model predicts 57–114 cases for HCV with the
marginal range being much smaller at 1–57 for HCV.
This range disparity, as outlined in Tables 2 and 3,
translates into substantial differences between the cu-
mulative estimates and the marginal estimates. For ex-
ample, according to Table 2, the benefit-cost ratio
ranges from 5.9 to 20.6 and the cost-effectiveness value
ranges from $1,705 to $5,969 (cost per lifetime treatment).SF in Vancouver using Jacobs et al.’s [30] model
averted Cost-effectiveness ratio HCV ($) Cost-benefit ratio HCV
1,705 20.6




(97,203, 97,203) (0.4, 0.4)
97,203 0.4
(97,203, 194,406) (0.4, 0.2)
97,203 0.4
(97,203, 194,406) (0.4, 0.2)
97,203 0.4
(97,203, 194,406) (0.4, 0.2)
97,203 0.4
(97,203, 194,406) (0.4, 0.2)
aring rate, 70% sharing rate).
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late into a much smaller return. This is particularly true with
respect to its benefit-cost and cost-effectiveness ratio; for in-
stance, the marginal benefit-cost ratio varies from 20.6 to
0.4. The marginal cost-effectiveness value for HCV ranges
from $1,705 to $97,203 (cost per lifetime treatment). Fur-
thermore, Table 3 shows that both cumulative benefit-cost
and cost-effectiveness ratios dwindle after the second SSF.
Finally, a sensitivity analysis was conducted for the
models employed. The sensitivity analysis pertained to
simulating different pipe-sharing rates (see Tables 2 and 3).
Similar to costing studies in Vancouver [37,38], Montreal
[39], and Ottawa [40] that used different needle-sharing
rates, the current analysis used 70% and 90% initial
pipe-sharing rates. Convincingly, the results from both
the baseline and sensitivity analysis demonstrate that
the establishment of an SSF by VANDU had saved tax-
payer money.
Discussion
The current analyses assessed whether the former SSF,
operated by VANDU in the DTES, would have had a net
positive fiscal impact on the Canadian society and
whether or not this policy initiative would save public
health-care funds by averting new HCV infections.
Moreover, the optimal number of SSFs was assessed based
on marginal cost-effectiveness and benefit-to-cost ratios.
The results presented here suggest that closing the only
unsanctioned SSF in Vancouver was a policy failure that
has potentially resulted in the spread of HCV within the
drug-user population. In fact, establishing more SSFs in
Vancouver’s DTES would be a beneficial and fiscally re-
sponsible in addition to the publically funded health-care
system. Based on the marginal counts, it should be noted
that although expansion beyond the second SSF location
may not provide the same economic return as the cumula-
tive estimates, it may still be considered cost-effective
given that the cumulative result was cost-effective beyond
the seventh potential location.
Though not outlined in this analysis, there are several
other benefits of opening a SSF that may add to the
existing financial benefits of a SSF. One such benefit is
the lowering of the risk of overdose, particularly for
those smoking heroin and methamphetamine [63]. In
British Columbia alone, 14 deaths have been attributed
to heroin smoking [27]. Given the medical supervision
of NIDUs, SSF has the potential to mitigate the risk of
overdose deaths.
Another benefit of opening a SSF is the potential to in-
crease detoxification and reduce risk behavior through
education. Research indicates that NIDUs will change
their risk behavior when provided with appropriate edu-
cation and treated with care [27]. Moreover, IDUs that
regularly use the Vancouver’s Insite are more likely toinitiate and maintain addiction treatment [4]. By visiting
a SSF, people who use drugs may utilize various services
such as mental health, counselling, and detoxification.
Furthermore, SSFs can be expected to reduce public
drug use in the same way that Vancouver’s Insite has
been able to reduce public drug-use behavior of IDUs.
In summary, not only on the use of crack among drug
users is on the rise but also the sharing of crack pipe
has been increasing at an alarming rate in Vancouver.
With recent research demonstrating the significant risk
of disease transmission via oral smoking equipment, the
current study determined whether the former unsanc-
tioned SSF operated by the grassroot organization,
VANDU, would cost less than the health-care conse-
quences of not having such a program in Vancouver.
The results indicated that the former facility not only
saved taxpayers’ money but also deserved to be ex-
panded instead of being forced to shut down. This in-
formation and analysis should be useful for policy
makers who seek to find practical, cost-effective solu-
tions to serious health-care problems in a climate of
scarce public resources.
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